News
QNCX
1.150
-2.54%
-0.030
Quince Therapeutics swings to Q1 net income of $35.91 million; operating loss narrows 2% to $14.59 million
PUBT · 5d ago
Weekly Report: what happened at QNCX last week (0504-0508)?
Weekly Report · 5d ago
BRIEF-Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom
Reuters · 05/08 10:24
ALPHABET DISSOLVES SHARE STAKE IN REPLIGEN - SEC FILING
Reuters · 05/08 10:03
Largest borrow rate increases among liquid names
TipRanks · 05/05 13:10
Weekly Report: what happened at QNCX last week (0427-0501)?
Weekly Report · 05/04 09:42
Quince Therapeutics Regains Nasdaq Bid Compliance Amid Valuation Risk
TipRanks · 04/28 22:04
Quince Therapeutics regains Nasdaq $1 minimum bid price compliance
PUBT · 04/28 21:05
Quince Therapeutics (QNCX) Price Target Increased by 900.00% to 40.80
NASDAQ · 04/28 02:02
Weekly Report: what happened at QNCX last week (0420-0424)?
Weekly Report · 04/27 09:43
Quince Therapeutics Appoints June Bray to Board
TipRanks · 04/22 21:33
Quince Therapeutics appoints June Bray to board as independent director
PUBT · 04/22 20:44
Largest borrow rate increases among liquid names
TipRanks · 04/21 12:49
Weekly Report: what happened at QNCX last week (0413-0417)?
Weekly Report · 04/20 09:42
Largest borrow rate increases among liquid names
TipRanks · 04/16 14:15
Weekly Report: what happened at QNCX last week (0406-0410)?
Weekly Report · 04/13 09:43
Upcoming Stock Splits This Week (April 13-17, 2026) – Stay Invested
TipRanks · 04/12 18:53
Quince Therapeutics trading halted, news pending
TipRanks · 04/10 23:53
Quince FY25 net loss widens 48% to $84 million
Reuters · 04/10 20:36
U.S. Earnings Preview: After Market Close April 10
Dow Jones · 04/10 19:31
More
Webull provides a variety of real-time QNCX stock news. You can receive the latest news about Quince through multiple platforms. This information may help you make smarter investment decisions.
About QNCX
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.